While DSS treatment initially triggered colitis in both IL10−/− and IL10+/− mice, colitis scores returned back to baseline in control IL10+/− mice, whereas they remained high in IL10−/− mice until the end of the 6-week experiment (Fig. 3a, b, Supplementary Fig. 4a). This evidence concerns the gene IL10 and colitis.